BR112017018305A2 - desacetoxitubulisina h e análogos da mesma - Google Patents
desacetoxitubulisina h e análogos da mesmaInfo
- Publication number
- BR112017018305A2 BR112017018305A2 BR112017018305A BR112017018305A BR112017018305A2 BR 112017018305 A2 BR112017018305 A2 BR 112017018305A2 BR 112017018305 A BR112017018305 A BR 112017018305A BR 112017018305 A BR112017018305 A BR 112017018305A BR 112017018305 A2 BR112017018305 A2 BR 112017018305A2
- Authority
- BR
- Brazil
- Prior art keywords
- analogs
- present disclosure
- deacetoxytubulisine
- provides
- compounds disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120613P | 2015-02-25 | 2015-02-25 | |
| US201662275667P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/019604 WO2016138288A1 (en) | 2015-02-25 | 2016-02-25 | Desacetoxytubulysin h and analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017018305A2 true BR112017018305A2 (pt) | 2018-04-17 |
Family
ID=56789084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017018305A BR112017018305A2 (pt) | 2015-02-25 | 2016-02-25 | desacetoxitubulisina h e análogos da mesma |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10808007B2 (https=) |
| EP (1) | EP3261443B1 (https=) |
| JP (1) | JP2018509404A (https=) |
| KR (1) | KR20170137725A (https=) |
| CN (1) | CN107529754A (https=) |
| AU (1) | AU2016222575A1 (https=) |
| BR (1) | BR112017018305A2 (https=) |
| CA (1) | CA2977589A1 (https=) |
| CL (1) | CL2017002170A1 (https=) |
| CO (1) | CO2017008600A2 (https=) |
| CR (1) | CR20170438A (https=) |
| DO (1) | DOP2017000202A (https=) |
| EA (1) | EA201791896A1 (https=) |
| EC (1) | ECSP17057131A (https=) |
| GT (1) | GT201700190A (https=) |
| HK (1) | HK1248069A1 (https=) |
| IL (1) | IL254089A0 (https=) |
| MX (1) | MX2017011024A (https=) |
| PE (1) | PE20180355A1 (https=) |
| PH (1) | PH12017501539A1 (https=) |
| SG (1) | SG11201706820RA (https=) |
| WO (1) | WO2016138288A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3350200A4 (en) | 2015-09-18 | 2019-03-27 | Wake Forest University Health Services | ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES |
| CA2914601A1 (en) * | 2015-12-11 | 2017-06-11 | Wake Forest University Health Sciences | Angiotensin-(1-7) analogs and methods relating thereto |
| US20210145771A1 (en) * | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| KR20200051733A (ko) * | 2017-09-08 | 2020-05-13 | 시애틀 지네틱스, 인크. | 튜불리신 및 그 중간물의 제조 공정 |
| WO2019108685A1 (en) * | 2017-11-29 | 2019-06-06 | William March Rice University | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith |
| JP7590328B2 (ja) | 2018-12-21 | 2024-11-26 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3814358B1 (en) * | 2019-07-11 | 2025-09-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing 2-indolinospirone compounds and intermediates thereof |
| US11694341B2 (en) | 2019-12-23 | 2023-07-04 | Texas Instmments Incorporated | Cascaded architecture for disparity and motion prediction with block matching and convolutional neural network (CNN) |
| CN112645833A (zh) * | 2021-01-29 | 2021-04-13 | 上海吉奉生物科技有限公司 | 一种(s)-2,6-二氨基-5-氧己酸的合成方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1523493T3 (da) | 2002-07-09 | 2013-12-02 | Alexander Doemling | Nye tubulysinanaloge |
| US7776814B2 (en) * | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| US20100047841A1 (en) * | 2007-02-27 | 2010-02-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of desacetoxytubulysin h and analogs thereof |
| WO2008138561A1 (en) | 2007-05-10 | 2008-11-20 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| EP2181101A2 (en) | 2007-07-20 | 2010-05-05 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysin d analogues |
| CN101909441B (zh) * | 2007-10-25 | 2015-05-13 | 恩多塞特公司 | 微管蛋白抑制剂及其制备方法 |
| EP2174947A1 (en) * | 2008-09-25 | 2010-04-14 | Universität des Saarlandes | Bioactive pre-tubulysins and use thereof |
| IT1394860B1 (it) | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| EP2322537A1 (en) | 2009-11-12 | 2011-05-18 | R & D Biopharmaceuticals Gmbh | Tubulin inhibitors |
| WO2011069116A1 (en) | 2009-12-04 | 2011-06-09 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| EP2409983A1 (en) | 2010-07-19 | 2012-01-25 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Tubulysin analogues |
| JP2013535220A (ja) * | 2010-08-06 | 2013-09-12 | エンドサイト，インコーポレイテッド | ツブリシンを調製するためのプロセス |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
| EA032203B1 (ru) * | 2014-04-11 | 2019-04-30 | МЕДИММЬЮН ЭлЭлСи | Производные тубулизина |
-
2016
- 2016-02-25 US US15/553,674 patent/US10808007B2/en active Active
- 2016-02-25 HK HK18107653.3A patent/HK1248069A1/zh unknown
- 2016-02-25 SG SG11201706820RA patent/SG11201706820RA/en unknown
- 2016-02-25 EP EP16756378.2A patent/EP3261443B1/en active Active
- 2016-02-25 AU AU2016222575A patent/AU2016222575A1/en not_active Abandoned
- 2016-02-25 CR CR20170438A patent/CR20170438A/es unknown
- 2016-02-25 KR KR1020177027116A patent/KR20170137725A/ko not_active Withdrawn
- 2016-02-25 EA EA201791896A patent/EA201791896A1/ru unknown
- 2016-02-25 CA CA2977589A patent/CA2977589A1/en not_active Abandoned
- 2016-02-25 JP JP2017545239A patent/JP2018509404A/ja active Pending
- 2016-02-25 CN CN201680023813.XA patent/CN107529754A/zh active Pending
- 2016-02-25 BR BR112017018305A patent/BR112017018305A2/pt not_active Application Discontinuation
- 2016-02-25 WO PCT/US2016/019604 patent/WO2016138288A1/en not_active Ceased
- 2016-02-25 PE PE2017001465A patent/PE20180355A1/es unknown
- 2016-02-25 MX MX2017011024A patent/MX2017011024A/es unknown
-
2017
- 2017-08-22 IL IL254089A patent/IL254089A0/en unknown
- 2017-08-25 CO CONC2017/0008600A patent/CO2017008600A2/es unknown
- 2017-08-25 DO DO2017000202A patent/DOP2017000202A/es unknown
- 2017-08-25 CL CL2017002170A patent/CL2017002170A1/es unknown
- 2017-08-25 GT GT201700190A patent/GT201700190A/es unknown
- 2017-08-25 PH PH12017501539A patent/PH12017501539A1/en unknown
- 2017-08-30 EC ECIEPI201757131A patent/ECSP17057131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107529754A (zh) | 2018-01-02 |
| US20180127463A1 (en) | 2018-05-10 |
| CL2017002170A1 (es) | 2018-06-08 |
| PH12017501539A1 (en) | 2018-02-05 |
| EA201791896A1 (ru) | 2018-02-28 |
| DOP2017000202A (es) | 2017-09-29 |
| CA2977589A1 (en) | 2016-09-01 |
| US10808007B2 (en) | 2020-10-20 |
| KR20170137725A (ko) | 2017-12-13 |
| AU2016222575A1 (en) | 2017-09-07 |
| HK1248069A1 (zh) | 2018-10-12 |
| IL254089A0 (en) | 2017-10-31 |
| CO2017008600A2 (es) | 2018-02-09 |
| CR20170438A (es) | 2018-01-30 |
| PE20180355A1 (es) | 2018-02-21 |
| MX2017011024A (es) | 2017-10-20 |
| GT201700190A (es) | 2018-11-26 |
| WO2016138288A1 (en) | 2016-09-01 |
| ECSP17057131A (es) | 2019-03-29 |
| EP3261443A1 (en) | 2018-01-03 |
| EP3261443B1 (en) | 2021-04-28 |
| SG11201706820RA (en) | 2017-09-28 |
| EP3261443A4 (en) | 2018-09-26 |
| JP2018509404A (ja) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
| BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| BR112017027414A2 (pt) | Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201492223A1 (ru) | Новые диазаспироциклоалканы и азаспироциклоалканы | |
| BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| BR112016028476A8 (pt) | compostos, composição, uso de um composto e método para o combate dos fungos nocivos | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| BR112015016585A2 (pt) | Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| MX374535B (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico. | |
| BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
| BR112017023080A2 (pt) | compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa | |
| BR112018006314A2 (pt) | composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
| BR112015016194A2 (pt) | compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida | |
| BR112017015116A2 (pt) | derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |